Format

Send to

Choose Destination
Bioorg Med Chem Lett. 2016 Jan 15;26(2):472-478. doi: 10.1016/j.bmcl.2015.11.089. Epub 2015 Nov 26.

Novel phenylalanine derived diamides as Factor XIa inhibitors.

Author information

1
Research and Development, Bristol-Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543, United States. Electronic address: leon.smith@bms.com.
2
Research and Development, Bristol-Myers Squibb Company, P.O. Box 5400, Princeton, NJ 08543, United States.

Abstract

The synthesis, structural activity relationships (SAR), and selectivity profile of a potent series of phenylalanine diamide FXIa inhibitors will be discussed. Exploration of P1 prime and P2 prime groups led to the discovery of compounds with high FXIa affinity, good potency in our clotting assay (aPPT), and high selectivity against a panel of relevant serine proteases as exemplified by compound 21. Compound 21 demonstrated good in vivo efficacy (EC50=2.8μM) in the rabbit electrically induced carotid arterial thrombosis model (ECAT).

KEYWORDS:

Anticoagulant; FXIa; Factor XIa; Serine protease; Thrombosis; aPTT

PMID:
26704266
DOI:
10.1016/j.bmcl.2015.11.089
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center